SigmaGraft
Private Company
Funding information not available
Overview
SigmaGraft is a commercial-stage, private medical device company specializing in biomaterials for dental and orthopedic regeneration. It operates a diversified portfolio of allograft, xenograft, and synthetic bone graft substitutes, membranes, and wound care products, supported by a strong contract manufacturing arm. The company leverages strategic collaborations with leading clinicians and universities to drive innovation and build clinical evidence. With a global commercial footprint and an ISO 13485-certified manufacturing facility, SigmaGraft is positioned in the growing regenerative medicine market.
Technology Platform
Portfolio of biomaterial technologies including processed allograft, xenograft, synthetic bioceramics (BCP, TCP), and collagen-based products for bone and tissue regeneration. Supported by ISO 13485-certified manufacturing capabilities for both internal products and contract services.
Opportunities
Risk Factors
Competitive Landscape
SigmaGraft competes in a crowded biomaterials market dominated by large players like Medtronic, Zimmer Biomet, and Straumann, as well as numerous specialized companies. It differentiates through a focus on high-quality products, clinician collaboration, and a diversified portfolio spanning dental and orthopedics. Its contract manufacturing arm also positions it differently from pure-play product companies.